Based on updated data from the TRUST-1 trial, taletrectinib is now approved by the FDA for patients with TKI-naive ROS1+ NSCLC.
|Poll|June 30, 2016
Patient Presents With Diarrhea of Several Weeks’ Duration
Author(s)Cesar A. Moran, MD
A 53-year-old man presents with diarrhea of several weeks’ duration. A biopsy of the small intestine is obtained. What is your diagnosis?
Advertisement
Advertisement
Related to this article
Misako Nagasaka, MD, PhD, explains how subcutaneous amivantamab’s shorter administration time benefits patients and infusion centers.
Jasmine Zain, MD, emphasized the importance of good patient counseling when outlining the potential risks of secondary T-cell malignancies following CAR T-cell therapy.
Misako Nagasaka, MD, PhD, discusses PALOMA-2’s 70% 3-year survival rate compared with historical MARIPOSA data for intravenous amivantamab.
Adult T-cell lymphoma and leukemia may warrant upfront allogeneic transplant, according to Mary Jo Lechowicz, MD.
Poster presentations at SOHO 2026 may inform multiple myeloma practice across the newly diagnosed and relapsed/refractory settings.
The IND clearance for IASO208, a CD20-targeted in vivo CAR-T therapy requiring no leukapheresis or lymphodepletion, enables advancement of a phase 1b trial.
The OMNI-EGFR inhibitor BH-30643 produced a 45% objective response rate among patients with EGFR C797S–positive disease in the phase 1/2 SOLARA trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
2
WCLC 2026: How Will The Small Cell Lung Cancer Paradigm Change?
3
SOHO 2026: Key Updates Across the Multiple Myeloma Continuum
4
Secondary T-Cell Malignancies: Identifying and Counseling After CAR T-Cell Therapy
5